益生菌和后生元制剂在化妆品和女性私护品中应用的机遇与挑战
Opportunities and Challenges of Application of the Probiotics/Postbiotics in Cosmetics and Female Personal Care Products
DOI: 10.12677/AMB.2023.121001, PDF, HTML, XML, 下载: 227  浏览: 641 
作者: 李冠楠, 王海玲, 王小咪, 孙海月, 王小兰, 黄生权*:仁和全域(上海)大健康研究院有限公司,上海
关键词: 益生菌后生元化妆品女性私护品机遇与挑战Probiotics Postbiotics Cosmetics Personal Care Products Opportunities and Challenges
摘要: 益生菌是能够给与宿主带来健康益处的活菌;而后生元是益生菌细胞膜的组成成份及其次级代谢产物的提取物,包含多种酶类、短链脂肪酸、维生素、氨基酸、脂多糖和磷壁酸等物质。益生菌/后生元相关产品在市场上越来越受到人们的青睐和关注。然而,目前市场上大多数益生菌/后生元的产品是不符合其定义标准的。近年来,化妆品产业已经出现了大量号称为益生菌/后生元的产品。这些益生菌/后生元制剂在个人护理产品中有多种潜在应用价值,特别是口腔、皮肤和私密护理产品,但仍需要对这些产品的标签和营销标准进行必要的监管,以确保消费者能正确的购买相关产品。本文综述了益生菌/后生元在个人护理行业的市场、监管和潜在应用。
Abstract: Probiotics, defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host,” are becoming increasingly popular and marketable. Postbiotics are the extracts of cell membrane components and secondary metabolites of non-viable probiotics, such as enzymes, short chain fatty acids, vitamins, amino acids, peptides, surface proteins, teichoic acids, lipopolysaccharides, etc. However, too many of the products currently labelled as probiotics fail to comply with the defining characteristics. In recent years, the cosmetic industry has increased the number of products classified as probiotics. While there are several potential applications for probiotics in personal care products, specifically for oral, skin, and intimate care, proper regulation of the labelling and marketing standards is still required to guarantee that consumers are indeed purchasing a probiotic product. This review explores the current market, regulatory aspects, and potential applications of probiotics in the personal care industry.
文章引用:李冠楠, 王海玲, 王小咪, 孙海月, 王小兰, 黄生权. 益生菌和后生元制剂在化妆品和女性私护品中应用的机遇与挑战[J]. 微生物前沿, 2023, 12(1): 1-9. https://doi.org/10.12677/AMB.2023.121001

1. 引言

美国食品药监局(Food and Drug Administration, FDA)中将化妆品定义为用于人体清洁、美化、增加吸引力或改变外观的产品(除纯肥皂产品),此定义常用于皮肤、头发和口腔护理等产品中。值得注意的是该描述中并不包含任何有关对人体健康的内容。目前,人们已经越来越关注体内微生物(病原和有益微生物)的组成和变化,这使研究人员试图通过改变外界因素来操纵宿主特有的微生物组从而促进人体健康,进而导致了益生菌/后生元相关产品有实质性的增长。益生菌是指当达到一定数量时能够给宿主带来健康益处的活体微生物;而后生元(又称类生元)是指灭活益生菌(包含破碎的菌体及其相关代谢产物)后的一类复杂混合物,其也能为宿主提供健康益处 [1] 。全球市场调查表明,益生菌等产品在化妆品领域的应用将以每年12%的速度增长 [2] 。本文将回顾益生菌/后生元在化妆品和个人护理品应用中的相关研究,以及探讨“益生菌/后生元化妆品”目前是如何营销的。

2. 皮肤化妆品

目前,市场上日益增加的益生菌/后生元产品不能代表科研成果已成功地向商业和消费者转化了,反而市面上出现的许多产品均不符合益生菌/后生元标准。生产厂家通过虚假宣传和滥用益生菌的概念来误导消费者从中牟利。事实上,即使益生菌的菌种种类和数量更多,但这些益生菌不在人体内部也不一定能够带来更多益处。令人惊讶的是许多产品的益生菌配方并非基于科学的研究结论,而是根据市场动态以及如何吸引消费者的因素。例如,有些产品广告上指出能够改善阴道健康,但产品里却使用的是没有任何科学记录和研究结果数据的菌株,并宣称该菌株能够与生殖道病原菌拮抗,同时提高宿主免疫力或恢复阴道内微环境稳态等。此外,生产商会付费雇佣伪专家和互联网搜索引擎等对产品进行宣传,使其产品获得高度评价用以说明该产品能够预防或治疗相关的阴道疾病。网上搜索产品经常会误导和迷惑消费者,并且会让从事医疗保健领域的人员对益生菌制品产生怀疑和不确定的态度。对于这个问题科学界需要进行重新声明,所有认作益生菌的菌株必须强制满足三个核心特征:1) 益生菌株需要进行特征描述(包括遗传学和表型学),以及在同行评审论文中给出详尽的实验记录和数据结果;2) 产品在使用时必须含有足够的活菌,这些微生物还要等同于其在临床研究中显示出的效果;3) 产品在给人体使用时,则必须含有明确的科学依据且应当注明使用方法、剂量和期限等。

由于益生菌/后生元这一概念拥有巨大的商业价值,导致某些专注皮肤护理的化妆品企业进入该产品生产领域,从而为其带来丰厚利润。如果产品标识上没有给出详细的菌株名称等信息,使用者将无法对该产品中的益生菌/后生元成分做出相应的功能评判。此外,许多产品中包含的是一些益生菌提取物、酵素或者菌体裂解物等,这些产品中并不含有活菌,而是符合后生元范畴,因此在产品宣传时不应写益生菌等字样。在美国市场目前至少有50种声称含有益生菌的产品已经商业化 [2] ,这些商品在介绍里常用的30中术语如图1所示,其中大多数是护肤品、除臭剂和护发品;此外,在产品功效说明中“平衡”皮肤微生物群,改善皮肤屏障,增强皮肤的整体外观成为最常见的说法。

Figure 1. The top 30 words used in the claims of cosmetics marketed as probiotics

图1. 富含益生菌的化妆品产品中常见的30个宣传术语

这些产品上的宣传术语是需要考证的,因为目前没有研究结果表明健康皮肤的微生物组组成是单一固定的。此外,皮肤分为许多层,在真皮、脂肪、毛囊、表皮中均可以检测到微生物的存在 [3] 。益生菌制品在宣传其功效能改变皮肤微生物组时,应具有大样本量的人体试验数据结果并且要指出产品是如何改变微生物组的,这样才能复合每个消费者对改善皮肤的要求。但是由于市面上大多数产品似乎不能进行相关研究,因此在产品宣传改变皮肤微生物的功效时都涉及了过度宣传和误导消费者的情况。测量皮肤的对比度、可见皮肤老化痕迹或斑点、肤色、黑色素和血红蛋白等项目 [4] ,这些指标的测量结果可以为益生菌产品提供实质性的护肤结论。某些益生菌菌株能够改善上皮和表皮屏障功能,由于这对皮肤的功能至关重要,所以这是对消费者极具吸引力的宣传点。一家化妆品公司的研究人员已经证明,长双歧杆菌益生菌的裂解物可以减少血管扩张、水肿、肥大细胞脱颗粒和细胞坏死因子TNF-α的释放,并使用表皮失水指标来评估其屏障功能,结果表明使用该产品后皮肤的护理效果确实有所改善 [5] 。一些护肤产品的说明上宣传其有效成分中含有益生菌发酵后的滤液(如:酵素或灭活的菌体),但在产品生产过滤过程中细菌细胞与其他一些较大的肽类分子等均会被过滤掉,这就导致根本无法达到护肤产品宣传中的特定功效,所以这类产品根本不属于益生菌/后生元制品。裂解物是细胞的外膜由于化学或物理过程而被破坏产生的 [6] ,这些制剂作为免疫调节剂已在医疗实践中使用了50年。它们可能含有上调宿主细胞免疫反应的细菌成分,它们在处理呼吸道感染方面特别有效 [7] 。鼠李糖乳杆菌Lacticaseibacillus rhamnosus GG和长双歧杆菌B. longum的裂解液可通过调节蛋白组分提高离体细胞的紧密连接屏障抗性 [8] 。虽然使用这些类型的制剂是有益的,但在得出结论和宣传之前仍需要在单菌株的基础上进行进一步的研究证实。例如,巨噬细胞的细胞组成、弹性和活化在不同菌株之间存在差异,甚至在同一物种内也是如此 [9] 。另一项研究中,乳酸菌裂解物改变了它们增加角质形成细胞上皮化的能力 [10] ,这些研究结果再次强调了在化妆品宣传之前需要充分核实菌株的特性。

目前,还不知道应用在化妆品中的益生菌/后生元的有效化学成份,这需要对菌株细胞壁的化学成份进行分析,包括使用基于代谢组学的液相色谱–串联质谱(LC-MS/MS)技术 [11] 或者更新的表面增强拉曼光谱(SERS)技术 [12] 。通过益生菌菌体的有效成份分析,我们能很快了解到不同菌株的代谢物类型和数量,因此它们在化妆品中应用在人体皮肤或组织上的功效也是不同的;同时,这也强调了化妆品在进入市场前应对菌株的整个细胞、裂解物和上清液等进行相关的试验测试必要性,从而能进一步了解到益生菌裂解物中的哪个成分在起作用。近来,许多研究已经提供了特定的益生菌菌株对人体皮肤健康的好处证据 [13] [14] [15] 。此外,抗衰老机制指明益生菌菌株可以调节pH值,减少氧化应激,保护皮肤免受光老化,提高皮肤屏障功能 [16] 。然而,化妆品行业需要在其生产标签中保持一致性和透明性,并在做产品宣传前应提供更多的直接科学证据。

3. 益生菌/后生元制品的局部给药和配方

研究证明口服益生菌能影响人体肠道菌群,从而可能改善皮肤状况,如特应性皮炎、痤疮或酒渣鼻 [17] [18] 。早期研究还显示,在妊娠期和生命早期使用益生菌可能会降低特应性皮炎的发病率和不利影响 [19] ,这意味着益生菌/后生元制剂具有免疫调节和改善成熟的肠道屏障功能 [20] 。冷冻干燥益生菌菌株是常见的,然而取决于所使用的干燥保护剂,菌株最终的生存能力可能会有所不同。最常用的保护剂是脱脂牛奶、血清、海藻糖、甘油、甜菜碱、腺苷醇、蔗糖、葡萄糖、乳糖和聚乙二醇,而这些保护剂可能与产品的预期用途或配方的物理化学特性不兼容 [21] 。微胶囊化可以延长益生菌的保质期和生存能力,它主要是为了确保微生物抵抗宿主消化系统的极端环境 [22] ,但它已被用于外用配方 [23] 。最常见的是,微生物被嵌入生物聚合物或脂质的保护基质中。对化妆品行业来说,从生产到价值链再到消费者,创造出能保持益生菌活性的外用配方是一项艰巨的任务。因为水分会让干燥的益生菌体水合繁殖或死亡,所以需要使用油基配方;然而,油机配方的菌体一旦涂抹在皮肤上,益生菌菌株的代谢谱会发生改变,从而难以产生宣传中产品的益生功效。

许多乳膏不是在无菌条件下生产的,因此产品中经常添加杀菌或抑菌作用的防腐剂。这些防腐剂不仅会影响益生菌菌株的生存能力,还会间接地改变微生物群。益生菌的监管主要与安全性有关。对于益生菌的商业化并没有特别的要求,产品的监管取决于其最终用途,无论是作为药物、医疗设备、食品、膳食补充剂还是化妆品。在加拿大和其它地方,宣传一种化妆品益生菌所需的描述性文件远低于宣称的一种药物 [2] 。不过,为了使利润最大化一些公司在化妆品上宣称具有减轻疾病的功效,而这么宣传时公司应该提供其作为药物或临床的证明文件。出于安全考虑,化妆品的微生物含量规定很低(眼妆产品应低于500 CFU/g,而其它产品低于1000 CFU/g的菌落单位) [2] 。这些产品中含有活菌是不可行的,因此不可能有真正的益生菌化妆品。然而,它们可能含有来自益生菌菌株的成分(包含细菌裂解物、发酵物和滤液),这属于后生元制品范畴,所以这些产品对人体还是有益的。北美市场上50种化妆品调查发现所有产品都没有列举出所用菌株名称,但是部分产品给出了菌种名称和组成成份(见图2)。有39种产品的标签上显示的成分都对应于发酵过程,如益生菌的提取物、滤液或者裂解液;酸奶中含有10%的益生菌成分,但是没有关于细菌类型的详细信息,也没有说明是否含有活细菌;而有6种产品中连含有的微生物制剂类型都没有说明 [2] 。由此可知,国内外市场上这些化妆品所宣传的功效信息大都是模糊的,从而让消费者对益生菌或后生元制剂配方的有效性无法评估。

Figure 2. Percentage chart of the ingredients listed in 50 cosmetic products

图2. 市场上50种化妆品中所罗列出的成份

在特定的监管下,一些含有益生菌/后生元制剂的化妆品作为局部治疗的药物是有潜在的应用价值的,并且这些产品可以被列为非处方药物(OTC)。如某些化妆品具有抗菌和免疫调节等特性,它们能够用于治疗痤疮、牛皮癣和皮炎等皮肤疾病,并且还有助于伤口愈合等功效。重要的是这些产品均需要进一步的人体研究和随机临床试验来验证它们的实际功效。

4. 女性私处护理的益生菌/后生元制品

魔镜电商市场调查报告显示,在2021年里女性私处护理类益生菌/后生元制剂类产品占总市场份额的26%,仅次于维护胃肠道健康类(占38%)的相关产品。由此可见,益生菌/后生元类私护产品深受光大女性消费者喜爱并且具有广阔的市场前景。通常,健康的阴道微环境是由大量的乳酸杆菌所维持的。但是各种诱因的影响下(如冲洗液、抗生素和性生活),会打乱女性阴道内微生态环境的平衡,从而导致细菌性阴道疾病、尿路感染、念珠菌病和其它等疾病。

这些情况为几十年前泌尿科医生就利用补充乳酸杆菌来治疗或恢复阴道健康提供了理论依据 [23] [24] ,从而妇科医生开始探索利用栓剂等形式补充益生乳酸杆菌来治疗相关的阴道疾病的方案 [25] 。从利用L. rhamnosus GR-1注入阴道开始 [26] ,就测试了一系列的具有益生活性的菌株,例如L. reuteri RC-1和L. crispatus CTV05用来减少尿路感染疾病的复发 [27] [28] ,L. rhamnosus IMC501连同L. paracasei IMC502来维持阴道稳态 [29] ,以及L. rhamnosus Lcr35对细菌型阴道疾病和外阴阴道念珠菌并的抑制作用等 [30] [31] 。由于抗菌剂治疗对泌尿生殖道有显著的负面影响及无法恢复阴道内稳态等问题,益生菌/后生元制品已经被联合使用在治疗相关疾病中。其中包括L. gasseri EN-153471 [32] 和L. rhamnosus GR-1加L. reuteri RC-14配合抗生素或抗真菌剂等 [33] [34] [35] 用于治疗细菌型阴道炎的方案。此外,当前已经报道了相关益生乳杆菌菌株在女性生殖道疾病治疗中的应用 [36] (见表1)。这些补充剂在阴道中能抑制病原体或与病原体竞争定植位点,同时还通过生产乳酸、过氧化氢和细菌素等生物活性物质来提供抗菌功效。因此,富含益生菌/后生元制剂的化妆品不仅有对皮肤的美容功效,在严格监管下还可能具有降低某些疾病风险的作用。当前《加拿大益生菌临床使用指导》已批准将益生菌株制作成栓剂直接用于阴道疾病治疗中 [23] [24] ;而其它产品是将益生菌/后生元制剂涂抹在卫生棉条上使用的 [37] [38] ,但还需要更多的研究来确认它们对宿主作用机理。

Table 1. Application of Lactobacillus in the treatment and prevention of female reproductive tract diseases

表1. 乳杆菌在女性生殖道疾病中的应用

益生菌/后生元产品的另一个关注点是能够显著性的减少与细菌性阴道疾病相关的泌尿生殖道恶臭,从而能明显提高女性的生活质量 [39] 。许多非益生菌/后生元产品(如阴道冲洗液、醋冲洗液和香料制品等)均宣传能有助于减少女性生殖道异味。然而,这些产品的功效尚不明确,并且还可能会通过性行为破坏阴道内的有益菌群从而增加感染相关疾病的风险 [40] [41] 。益生菌/后生元制剂的优势在于其生长和产生代谢产物的能力,这些代谢产物可降解或中和恶臭化合物 [42] [43] 。但根据此类产品的性质,其应当注册为OTC药物,而不是化妆品或私人护理类产品。此外,市场上已经开发了含有益生乳酸杆菌的外用凝胶,这些产品对于治疗外阴阴道念珠菌病具有很好的效果 [44] 。目前,益生菌/后生元产品在泌尿生殖道的中应用并不严格属于化妆品的定义,即旨在恢复或改善一个人的外观。同样,根据“外观”的定义和解释,用于减少口臭的应用也不合适 [45] [46] [47] 而在外用乳膏中加入乳酸杆菌可以减少痤疮的症状,却可以作为化妆品使用 [48] 。

5. 展望

人体上充满了各种各样的微生物,某些微生物对宿主的健康是有益的,因此个人微生态健康管理的观念逐步受到人们的认可。在个人护肤和私处护理等方面,化妆品公司已经开发了相关的益生菌/后生元产品并且从中获得了丰厚的利润。仅在二十年前,益生菌、益生元、微生物组和后生元等相关术语还没有出现在化妆品产品的宣传中,而现在这些词汇已经让消费者们广泛熟知。然而,如果这些产品宣传的使用效果与有力的科学结论相一致,并且能揭示所应用的菌株的作用机制,那么使用这些产品才能令人信服,但是目前市面上还很少见到这类产品。此外,在监管角度上讲,应当出台一个合理的生产标准和条例从而严格监管和区分化妆品和OTC产品,以确保减少产品宣传过程中误导消费者的情况。因此,监督管理机构要不断更新升级监管政策(如:益生菌/后生元产品在网上备案),并且出台相关法案引导生产商在推出全新产品前,就需要对产品的进行临床验证以及确保产品的安全性。此外,监管部门还需要制定在生产、储存和应用时含有益生菌/后生元制剂产品的标准。未经证实功效的产品不应批准上市,从而鼓励生产商构建一个健全的研发团队,为研发对人类有重要价值的益生菌/后生元产品奠定扎实的基础。综上,目前建立一个良好的益生菌/后生元产品的市场环境是任重而道远的,但是随着该领域市场不断发展和扩大,相关监管机构和部门势必会进一步完成对该领域产品的监管职责,出于对消费者负责的态度给益生菌/后生元制剂市场一个良好健全的导向。

NOTES

*通讯作者。

参考文献

[1] 刘颖, 张欢, 牛超杰, 袁阳华, 常超. 后生元的开发与应用研究新趋势[J]. 武汉轻工大学学报, 2021, 40(5): 14-20, 60.
[2] Puebla-Barragan, S. and Reid, G. (2021) Probiotics in Cosmetic and Personal Care Products: Trends and Challenges. Molecules, 26, Article No. 1249.
https://doi.org/10.3390/molecules26051249
[3] Nakatsuji, T., Chiang, H.-I., Jiang, S.B., Nagarajan, H., Zengler, K. and Gallo, R.L. (2013) The Microbiome Extends to Subepidermal Compartments of Normal Skin. Nature Communications, 4, Article No. 1431.
https://doi.org/10.1038/ncomms2441
[4] Matts, P.J. (2008) New Insights into Skin Appearance and Measurement. Journal of Investigative Dermatology Symposium Proceedings, 13, 6-9.
https://doi.org/10.1038/jidsymp.2008.6
[5] Guéniche, A., Bastien, P., Ovigne, J.M., Kermici, M., Courchay, G., Chevalier, V., Breton, L. and Castiel-Higounenc, I. (2010) Bifidobacterium longum Lysate, a New Ingredient for Reactive Skin. Experimental Dermatology, 19, e1-e8.
https://doi.org/10.1111/j.1600-0625.2009.00932.x
[6] Klein, G., Schanstra, J.P., Hoffmann, J., Mischak, H., Siwy, J. and Zimmermann, K. (2013) Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products. PLoS One, 8, e66682.
https://doi.org/10.1371/journal.pone.0066682
[7] Villa, E., Garelli, V., Braido, F., Melioli, G. and Canonica, G.W. (2010) May We Strengthen the Human Natural Defenses with Bacterial Lysates? World Allergy Organization Journal, 3, S17-S23.
https://doi.org/10.1186/1939-4551-3-S2-S17
[8] Sultana, R., McBain, A.J. and O’Neill, C.A. (2013) Strain-Dependent Augmentation of Tight-Junction Barrier Function in Human Primary Epidermal Keratinocytes by Lactobacillus and Bifidobacterium Lysates. Applied and Environmental Microbiology, 79, 4887-4894.
https://doi.org/10.1128/AEM.00982-13
[9] Mokrozub, V.V., Lazarenko, L.M., Sichel, L.M., Babenko, L.P., Lytvyn, P.M., Demchenko, O.M., Melnichenko, Y.O., Boyko, N.V., Biavati, B., Digioia, D., et al. (2015) The Role of Beneficial Bacteria Wall Elasticity in Regulating Innate Immune Response. EPMA Journal, 6, Article No. 13.
https://doi.org/10.1186/s13167-015-0035-1
[10] Mohammedsaeed, W., Cruickshank, S., McBain, A.J. and O’Neill, C.A. (2015) Lactobacillus rhamnosus GG Lysate Increases Re-Epithelialization of Keratinocyte Scratch Assays by Promoting Migration. Scientific Reports, 5, Article No. 16147.
https://doi.org/10.1038/srep16147
[11] Ankrah, N.Y.D., May, A.L., Middleton, J.L., Jones, D.R., Hadden, M.K., Gooding, J.R., LeCleir, G.R., Wilhelm, S.W., Campagna, S.R. and Buchan, A. (2014) Phage Infection of an Environmentally Relevant Marine Bacterium Alters Host Metabolism and Lysate Composition. The ISME Journal, 8, 1089-1100.
https://doi.org/10.1038/ismej.2013.216
[12] Genova, E., Pelin, M., Decorti, G., Stocco, G., Sergo, V., Ventura, A. and Bonifacio, A. (2018) SERS of Cells: What Can We Learn from Cell Lysates? Analytica Chimica Acta, 1005, 93-100.
https://doi.org/10.1016/j.aca.2017.12.002
[13] Navarro-López, V., Martínez-Andrés, A., Ramírez-Boscá, A., Ruzafa-Costas, B., Núñez-Delegido, E., Carrión-Gutiérrez, M.A., Prieto-Merino, D., Codoñer-Cortés, F., Ramón-Vidal, D., Genovés-Martínez, S., et al. (2019) Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial. Acta Dermato-Venereologica, 99, 1078-1084.
https://doi.org/10.2340/00015555-3305
[14] Yu, Y., Dunaway, S., Champer, J., Kim, J. and Alikhan, A. (2020) Changing Our Microbiome: Probiotics in Dermatology. British Journal of Dermatology, 182, 39-46.
https://doi.org/10.1111/bjd.18659
[15] Korpela, K., Salonen, A., Vepsäläinen, O., Suomalainen, M., Kolmeder, C., Varjosalo, M., Miettinen, S., Kukkonen, K., Savilahti, E., Kuitunen, M., et al. (2018) Probiotic Supplementation Restores Normal Microbiota Composition and Function in Antibiotic-Treated and in Caesarian-Born Infants. Microbiome, 6, Article No. 182.
https://doi.org/10.1186/s40168-018-0567-4
[16] Sharma, D., Kober, M.-M. and Bowe, W.P. (2016) Anti-Aging Effects of Probiotics. Journal of Drugs in Dermatology, 15, 9-12.
[17] Jung, G.W., Tse, J.E., Guiha, I. and Rao, J. (2013) Prospective, Randomized, Open-Label Trial Comparing the Safety, Efficacy, and Tolerability of an Acne Treatment Regimen with and without a Probiotic Supplement and Minocycline in Subjects with Mild to Moderate acne. Journal of Cutaneous Medicine and Surgery, 17, 114-122.
https://doi.org/10.2310/7750.2012.12026
[18] Knackstedt, R., Knackstedt, T. and Gatherwright, J. (2020) The Role of Topical Probiotics in Skin Conditions: A Systematic Review of Animal and Human Studies and Implications for Future Therapies. Experimental Dermatology, 29, 15-21.
https://doi.org/10.1111/exd.14032
[19] Kalliomäki, M., Salminen, S., Poussa, T., Arvilommi, H. and Isolauri, E. (2003) Probiotics and Prevention of Atopic Disease: 4-Year Follow-up of a Randomized Placebo-Controlled Trial. Lancet, 361, 1869-1871.
https://doi.org/10.1016/S0140-6736(03)13490-3
[20] Isolauri, E., Kalliomaki, M., Laitinen, K. and Salminen, S. (2008) Modulation of the Maturing Gut Barrier and Microbiota: A Novel Target in Allergic Disease. Current Pharmaceutical Design, 14, 1368-1375.
https://doi.org/10.2174/138161208784480207
[21] Hubálek, Z. (2003) Protectants Used in the Cryopreservation of Microorganisms. Cryobiology, 46, 205-229.
https://doi.org/10.1016/S0011-2240(03)00046-4
[22] Yao, M., Xie, J., Du, H., McClements, D.J., Xiao, H. and Li, L. (2020) Progress in Microencapsulation of Probiotics: A Review. Comprehensive Reviews in Food Science and Food Safety, 19, 857-874.
https://doi.org/10.1111/1541-4337.12532
[23] Puebla-Barragan, S. and Reid, G. (2019) Forty-Five-Year Evolution of Probiotic Therapy. Microbial Cell, 6, 184-196.
https://doi.org/10.15698/mic2019.04.673
[24] Bruce, A.W., Chadwick, P., Hassan, A. and VanCott, G.F. (1973) Recurrent Urethritis in Women. Canadian Medical Association Journal, 108, 973-976.
[25] Kale, V.V., Trivedi, R.V., Wate, S.P. and Bhusari, K.P. (2005) Development and Evaluation of a Suppository Formulation Containing Lactobacillus and Its Application in Vaginal Diseases. Annals of the New York Academy Science, 1056, 359-365.
https://doi.org/10.1196/annals.1352.017
[26] Bruce, A.W. and Reid, G. (1988) Intravaginal Instillation of Lactobacilli for Prevention of Recurrent Urinary Tract Infections. Canadian Journal of Microbiology, 34, 339-343.
https://doi.org/10.1139/m88-062
[27] Reid, G., Bruce, A.W., Fraser, N., Heinemann, C., Owen, J. and Henning, B. (2001) Oral Probiotics Can Resolve Urogenital Infections. FEMS Immunology & Medical Microbiology, 30, 49-52.
https://doi.org/10.1111/j.1574-695X.2001.tb01549.x
[28] Stapleton, A.E., Au-Yeung, M., Hooton, T.M., Fredricks, D.N., Roberts, P.L., Czaja, C.A., Yarova-Yarovaya, Y., Fiedler, T., Cox, M. and Stamm, W.E. (2011) Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection. Clinical Infectious Diseases, 52, 1212-1217.
https://doi.org/10.1093/cid/cir183
[29] Verdenelli, M.C., Cecchini, C., Coman, M.M., Silvi, S., Orpianesi, C., Coata, G., Cresci, A. and Di Renzo, G.C. (2016) Impact of Probiotic SYNBIO® Administered by Vaginal Suppositories in Promoting Vaginal Health of Apparently Healthy Women. Current Microbiology, 73, 483-490.
https://doi.org/10.1007/s00284-016-1085-x
[30] Rossi, A., Rossi, T., Bertini, M. and Caccia, G. (2010) The Use of Lactobacillus rhamnosus in the Therapy of Bacterial Vaginosis. Evaluation of Clinical Efficacy in a Population of 40 Women Treated for 24 Months. Archives of Gynecology and Obstetrics, 281, 1065-1069.
https://doi.org/10.1007/s00404-009-1287-6
[31] Petricevic, L. and Witt, A. (2008) The Role of Lactobacillus caseirhamnosus Lcr35 in Restoring the Normal Vaginal Flora after Antibiotic Treatment of Bacterial Vaginosis. BJOG: An International Journal of Obstetrics & Gynaecology, 115, 1369-1374.
https://doi.org/10.1111/j.1471-0528.2008.01882.x
[32] Larsson, P.G., Brandsborg, E., Forsum, U., Pendharkar, S., Andersen, K.K., Nasic, S., Hammarström, L. and Marcotte, H. (2011) Extended Antimicrobial Treatment of Bacterial Vaginosis Combined with Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses. BMC Infectious Diseases, 11, Article No. 223.
https://doi.org/10.1186/1471-2334-11-223
[33] Anukam, K., Osazuwa, E., Ahonkhai, I., Ngwu, M., Osemene, G., Bruce, A.W. and Reid, G. (2006) Augmentation of Antimicrobial Metronidazole Therapy of Bacterial Vaginosis with Oral Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: Randomized, Double-Blind, Placebo-Controlled Trial. Microbes and Infection, 8, 1450- 1454.
https://doi.org/10.1016/j.micinf.2006.01.003
[34] Martinez, R.C.R., Franceschini, S.A., Patta, M.C., Quintana, S.M., Candido, R.C., Ferreira, J.C., De Martinis, E.C.P. and Reid, G. (2009) Improved Treatment of Vulvovaginal Candidiasis with Fluconazole Plus Probiotic Lactobacillus rhanosus GR-1 and Lactobacillus reuteri RC-14. Letters in Applied Microbiology, 48, 269-274.
https://doi.org/10.1111/j.1472-765X.2008.02477.x
[35] Vujic, G., Knez, A.J., Stefanovic, V.D. and Vrbanovic, V.K. (2013) Efficacy of Orally Applied Probiotic Capsules for Bacterial Vaginosis and Other Vaginal Infections: A Double-Blind, Randomized, Placebo-Controlled Study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 168, 75-79.
https://doi.org/10.1016/j.ejogrb.2012.12.031
[36] 何红鹏, 李伟强, 高歌, 赵蕾, 郭昌林, 刘浩成. 阴道益生菌制剂在女性生殖道疾病治疗中的应用研究概述[J]. 天津科技大学学报, 2021, 36(6): 75-80.
[37] Sauperl, O., Zabret, A. and Zemljič, L.F. (2020) Development of Advanced Sanitary Materials with the Use of Probiotic Paste. Journal of Engineered Fibers and Fabrics, 15, Article ID: 155892502092221.
https://doi.org/10.1177/1558925020922215
[38] Handalishy, I., Behery, M., Elkhouly, M., Farag, E.A. and Elsheikh, W.A. (2014) Comparative Study between Probiotic Vaginal Tampons and Oral Metronidazole in Treatment of Bacterial Vaginosis. AAMJ, 12, 185-203.
[39] Bilardi, J.E., Walker, S., Temple-Smith, M., McNair, R., Mooney-Somers, J., Bellhouse, C., Fairley, C.K., Chen, M.Y. and Bradshaw, C. (2013) The Burden of Bacterial Vaginosis: Women’s Experience of the Physical, Emotional, Sexual and Social Impact of Living with Recurrent Bacterial Vaginosis. PLoS One, 8, e74378.
https://doi.org/10.1371/journal.pone.0074378
[40] Fashemi, B., Delaney, M.L., Onderdonk, A.B. and Fichorova, R.N. (2013) Effects of Feminine Hygiene Products on the Vaginal Mucosal Biome. Microbial Ecology in Health and Disease, 24, Article 19703.
https://doi.org/10.3402/mehd.v24i0.19703
[41] Brotman, R.M., Klebanoff, M.A., Nansel, T.R., Andrews, W.W., Schwebke, J.R., Zhang, J., Yu, K.F., Zenilman, J.M. and Scharfstein, D.O. (2008) A Longitudinal Study of Vaginal Douching and Bacterial Vaginosis—A Marginal Structural Modeling Analysis. American Journal of Epidemiology, 168, 188-196.
https://doi.org/10.1093/aje/kwn103
[42] McMillan, A., Rulisa, S., Sumarah, M., Macklaim, J.M., Renaud, J., Bisanz, J.E., Gloor, G.B. and Reid, G. (2015) A multi-platform Metabolomics Approach Identifies Highly Specific Biomarkers of Bacterial Diversity in the Vagina of Pregnant and Non-Pregnant Women. Scientific Reports, 5, Article No. 14174.
https://doi.org/10.1038/srep14174
[43] Puebla-Barragan, S., Renaud, J., Sumarah, M. and Reid, G. (2020) Malodorous Biogenic Amines in Escherichia coli-Caused Urinary Tract Infections in Women—A Metabolomics Approach. Scientific Reports, 10, Article No. 9703.
https://doi.org/10.1038/s41598-020-66662-x
[44] Donders, G., Bellen, G., Oerlemans, E., Claes, I., Ruban, K., Henkens, T., Kiekens, F. and Lebeer, S. (2020) The Use of 3 Selected Lactobacillary Strains in Vaginal Probiotic Gel for the Treatment of Acute Candida Vaginitis: A Proof- of-Concept Study. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1551-1558.
https://doi.org/10.1007/s10096-020-03868-x
[45] Iwamoto, T., Suzuki, N., Tanabe, K., Takeshita, T. and Hirofuji, T. (2010) Effects of Probiotic Lactobacillus salivarius WB21 on Halitosis and Oral Health: An Open-Label Pilot Trial. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 110, 201-208.
https://doi.org/10.1016/j.tripleo.2010.03.032
[46] Masdea, L., Kulik, E., Hauser-Gerspach, I., Ramseier, A., Filippi, A., Waltimo, T., Masdea, L., Kulik, E., Hauser-Ger- spach, I., Ramseier, A., et al. (2012) Antimicrobial Activity of Streptococcus salivarius K12 on Bacteria Involved in Oral Malodour. Archives of Oral Biology, 57, 1041-1047.
https://doi.org/10.1016/j.archoralbio.2012.02.011
[47] Burton, J.P., Chilcott, C.N., Moore, C.J., Speiser, G. and Tagg, J.R. (2006) A Preliminary Study of the Effect of Probiotic Streptococcus salivarius K12 on Oral Malodour Parameters. Journal of Applied Microbiology, 100, 754-764.
https://doi.org/10.1111/j.1365-2672.2006.02837.x
[48] Lebeer, S., Oerlemans, E., Claes, I., Wuyts, S., Henkens, T., Spacova, I., van den Broek, M., Tuyaerts, I., Wittouck, S., De Boeck, I., et al. (2018) Topical Cream with Live Lactobacilli Modulates the Skin Microbiome and Reduce Acne Symptoms. bioRxiv.
https://doi.org/10.1101/463307